Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on October 6, 2011, regarding events occurring on September 30, 2011. The company is incorporated in Delaware and operates from Annapolis, Maryland.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements.
Material Changes and Events
Under Item 5.02, the Board of Directors granted equity compensation to two executive officers, including President and CEO Eric I. Richman:
- Incentive Stock Options: An aggregate of 50,000 shares (25,000 to Mr. Richman) granted under the 2007 Long-Term Incentive Compensation Plan.
- Option Terms: Ten-year term, exercisable at $1.76 per share (closing price on September 30, 2011), vesting in full on September 30, 2012.
- Restricted Stock: An aggregate of 50,000 shares (25,000 to Mr. Richman) granted under the same plan, vesting in full on December 31, 2011.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure of the compensation grants.
Key Facts for Investor Verification
- Verify the total number of shares outstanding and the dilution impact of the 100,000 new equity awards (50,000 options + 50,000 restricted shares).
- Confirm the vesting schedules: options vest in one year (Sept 2012) while restricted stock vests in approximately three months (Dec 2011).
- Note the exercise price of $1.76 relative to the company's current stock price to assess the intrinsic value of the options.